Promacta® (eltrombopag) – Expanded indication
November 16, 2018 - Novartis announced the FDA approval of Promacta (eltrombopag), in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia (SAA).
Download PDF
